20 April 2017
CanSino raises $65m from high rollers
Existing investor Lilly Asia Ventures returned to take part in a round that will support the late stage development and commercialisation of four vaccine candidates.
Author: Robert Lavine, News Editor
China-based vaccine developer Tianjin CanSino Biotechnology closed a $65m funding round on Tuesday backed by Lilly Asia Ventures, a strategic investment vehicle for pharmaceutical company Eli Lilly.